Trial · NCT00872989

S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00872989, Phase 2, Completed, SWOG Cancer Research Network; results first posted 2016-12-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. Trials, record NCT00872989. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00872989

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT number: NCT00872989
Status: Completed
Phases: Phase 2
Enrollment: 129 participants, actual
Lead sponsor: SWOG Cancer Research Network
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: docetaxel, vandetanib
First posted: 2009-04-01
Last updated: 2016-12-19
Results first posted: 2016-12-19

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression Free Survival (PFS)	Disease assessments were performed every 6 weeks for as long as the patient remained on protocol, up to 5 years	From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression free are censored at date of last contact.
Secondary	Number of Participants With a Complete Response, Partial Response, Stable Disease, or Increasing Disease	Disease assessment for responses were performed every 6 weeks for as long as the patient remained on protocol treatment, up to 5 years.	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR in conjunction with measured CA125 responses
Secondary	Overall Survival	every 3 months for two years and then every 6 months for 3 years	From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.
Secondary	Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs	Toxicity assessment was evaluated before each treatment cycle (21 days), up to 5 years.	Adverse Events (AEs) are reported by CTCAE Version 3.0. Only adverse events that are possibly, probably or definitely related to study drug are reported.
Secondary	Time to Treatment Failure	Disease assessments were performed every 6 weeks for as long as the patient remained on protocol, up to 5 years.	Time to treatment failure after treatment with single agent vandetanib following progression on single agent docetaxel. Disease assessments were performed every 6 weeks for as long as the patient remained on protocol, up to 5 years.
Secondary	Number of Participants With a Complete Response, Partial Response, Stable Disease, or Increasing Disease After Treatment With Single Agent Vandetanib Following Progression on Single Agent Docetaxel	Disease assessments were performed every 6 weeks for as long as the patient remained on protocol, up to 5 years.	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR in conjunction with measured CA125 responses

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression Free Survival (PFS)	Disease assessments were performed every 6 weeks for as long as the patient remained on protocol, up to 5 years		months	MEDIAN
SECONDARY	Number of Participants With a Complete Response, Partial Response, Stable Disease, or Increasing Disease	Disease assessment for responses were performed every 6 weeks for as long as the patient remained on protocol treatment, up to 5 years.	Analysis of response is in the subset of patients who had at least one measurable target lesion at baseline.	participants	NUMBER
SECONDARY	Overall Survival	every 3 months for two years and then every 6 months for 3 years		months	MEDIAN
SECONDARY	Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs	Toxicity assessment was evaluated before each treatment cycle (21 days), up to 5 years.	Eligible patients who had received the protocol treatments were included in the adverse event summaries. Any CTCAE 3.0 event of Grade 3 (serious), Grade 4 (life threatening) or Grade 5 (fatal) which were deemed to be related to protocol treatment are included.	Participants	NUMBER
SECONDARY	Time to Treatment Failure	Disease assessments were performed every 6 weeks for as long as the patient remained on protocol, up to 5 years.		Months	MEDIAN
SECONDARY	Number of Participants With a Complete Response, Partial Response, Stable Disease, or Increasing Disease After Treatment With Single Agent Vandetanib Following Progression on Single Agent Docetaxel	Disease assessments were performed every 6 weeks for as long as the patient remained on protocol, up to 5 years.	Analysis of response is in the subset of patients who had at least one measurable target lesion at baseline.	participants	NUMBER

Source ClinicalTrials.gov

Results by group178

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Progression Free Survival (PFS)	Arm I: Docetaxel		3.5	95% Confidence Interval 2.3 to 4.6	months
Progression Free Survival (PFS)	Arm II: Docetaxel + Vandetanib		3.0	95% Confidence Interval 1.6 to 4.3	months
Number of Participants With a Complete Response, Partial Response, Stable Disease, or Increasing Disease	Arm I: Docetaxel	Complete Response	0		participants
Number of Participants With a Complete Response, Partial Response, Stable Disease, or Increasing Disease	Arm II: Docetaxel + Vandetanib	Complete Response	0		participants
Number of Participants With a Complete Response, Partial Response, Stable Disease, or Increasing Disease	Arm I: Docetaxel	Partial Response	5		participants
Number of Participants With a Complete Response, Partial Response, Stable Disease, or Increasing Disease	Arm II: Docetaxel + Vandetanib	Partial Response	6		participants
Number of Participants With a Complete Response, Partial Response, Stable Disease, or Increasing Disease	Arm I: Docetaxel	Unconfirmed Complete Response	1		participants
Number of Participants With a Complete Response, Partial Response, Stable Disease, or Increasing Disease	Arm II: Docetaxel + Vandetanib	Unconfirmed Complete Response	0		participants
Number of Participants With a Complete Response, Partial Response, Stable Disease, or Increasing Disease	Arm I: Docetaxel	Unconfirmed Partial Response	2		participants
Number of Participants With a Complete Response, Partial Response, Stable Disease, or Increasing Disease	Arm II: Docetaxel + Vandetanib	Unconfirmed Partial Response	2		participants

1 to 10 of 178Source ClinicalTrials.gov

See all 178 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Arm I: Docetaxel	66
Overall Study	STARTED	Arm II: Docetaxel + Vandetanib	63
Overall Study	COMPLETED	Arm I: Docetaxel	1
Overall Study	COMPLETED	Arm II: Docetaxel + Vandetanib	0
Overall Study	NOT COMPLETED	Arm I: Docetaxel	65
Overall Study	NOT COMPLETED	Arm II: Docetaxel + Vandetanib	63

Source ClinicalTrials.gov

Adverse events339

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Docetaxel	47	64
other	Anemia	Blood and lymphatic system disorders	Docetaxel + Vandetanib	27	61
other	Anemia	Blood and lymphatic system disorders	Vandetanib	11	33
other	Palpitations	Cardiac disorders	Docetaxel	0	64
other	Palpitations	Cardiac disorders	Docetaxel + Vandetanib	4	61
other	Palpitations	Cardiac disorders	Vandetanib	0	33
other	Sinus tachycardia	Cardiac disorders	Docetaxel	1	64
other	Sinus tachycardia	Cardiac disorders	Docetaxel + Vandetanib	2	61
other	Sinus tachycardia	Cardiac disorders	Vandetanib	2	33
other	Watering eyes	Eye disorders	Docetaxel	5	64

1 to 10 of 339Source ClinicalTrials.gov

See all 339 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Docetaxel
Total, all-cause mortality	Docetaxel + Vandetanib
Total, all-cause mortality	Vandetanib
Total, other adverse events	Docetaxel	61	64
Total, other adverse events	Docetaxel + Vandetanib	59	61
Total, other adverse events	Vandetanib	32	33
Total, serious adverse events	Docetaxel	1	64
Total, serious adverse events	Docetaxel + Vandetanib	31	61
Total, serious adverse events	Vandetanib	7	33

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
24709487	RESULT	PubMed
37185961	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA032102	Southwest Oncology Group Treatment Grant	BLANKE, CHARLES D.	OREGON HEALTH & SCIENCE UNIVERSITY	NATIONAL CANCER INSTITUTE	1985 to 2013

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00872989

GET https://conductscience.org/api/trials/v1/NCT00872989/results?page=2

API reference For AI assistants